Graphite mine digging sedimentation tank in Luobei County, Hegan
Publish: 2021-04-24 21:22:25
1.
bus line: subway line S3 → No.136, the whole journey is about 19.7 km
1. Take subway line S3 from Nanjing South Station, pass 11 stations, and reach Liucun station
2. Walk about 570 meters to hongdayang decoration City Station
3. Take No.136, pass 2 stations, and reach Shilin Park Station (also take no.d9, No.158, No.183)
4. Walk about 560 meters, Arrive at Suning Yuhua logistics center
2. The largest logistics market,
the main logistics market in Nanjing is in 312 national highway, Xianlin auto parts base, and the vehicles of the whole country are distributed here! There are about thousands of vehicles all over the country in the parking lot. There are all kinds of vehicles<
Dingjiazhuang logistics center
OK, most logistics special line warehouses are here<
Wangjiawan logistics center
I don't think it's very good. There are no cars. It's mainly in Xianlin
there is a logistics market in the urban area. At No.27 Jianning Road, the market is not very big, but it also undertakes goods from all over the country, less than carload!
the main logistics market in Nanjing is in 312 national highway, Xianlin auto parts base, and the vehicles of the whole country are distributed here! There are about thousands of vehicles all over the country in the parking lot. There are all kinds of vehicles<
Dingjiazhuang logistics center
OK, most logistics special line warehouses are here<
Wangjiawan logistics center
I don't think it's very good. There are no cars. It's mainly in Xianlin
there is a logistics market in the urban area. At No.27 Jianning Road, the market is not very big, but it also undertakes goods from all over the country, less than carload!
3. Nanjing Suning logistics base is located in Yuhua modern comprehensive logistics park, which integrates Suning Electric Service headquarters, logistics distribution center, after-sales service center, customer service call center, training center and national data center. It is the third generation comprehensive logistics base of Suning Electric, covering an area of 350 mu
the logistics distribution center of the base adopts the construction mode of combining the ordinary shelf warehouse with the automatic three-dimensional warehouse. The warehouse area is 46000 square meters, and the advanced storage, handling, transportation, sorting equipment and information management system are introced, which can realize the mechanization, automation, information operation and management of logistics. The daily throughput capacity can reach 17000 sets, The maximum number of units out of the warehouse is 24000. Using WMS (warehouse management system) warehouse management system in logistics distribution center can effectively support different information needs of different users, balance workload more reasonably, rece level errors, improve inventory accuracy and storage space utilization, and rece operation cost. TMS (transportation management system), another important core software system of logistics distribution center, can optimize route scheling plan for retail distribution and long-distance distribution of orders, effectively rece distribution mileage and working time, and completely change the traditional operation mode of manual scheling. The planned multimedia monitoring system, including image monitoring, communication and video, information gathering, command and dispatching, can monitor and manage all chain stores, logistics centers and after-sales outlets in real time. After completion, Suning logistics distribution center can realize 24-hour direct door-to-door delivery within 200 km, supporting annual sales of 12 billion yuan.
the logistics distribution center of the base adopts the construction mode of combining the ordinary shelf warehouse with the automatic three-dimensional warehouse. The warehouse area is 46000 square meters, and the advanced storage, handling, transportation, sorting equipment and information management system are introced, which can realize the mechanization, automation, information operation and management of logistics. The daily throughput capacity can reach 17000 sets, The maximum number of units out of the warehouse is 24000. Using WMS (warehouse management system) warehouse management system in logistics distribution center can effectively support different information needs of different users, balance workload more reasonably, rece level errors, improve inventory accuracy and storage space utilization, and rece operation cost. TMS (transportation management system), another important core software system of logistics distribution center, can optimize route scheling plan for retail distribution and long-distance distribution of orders, effectively rece distribution mileage and working time, and completely change the traditional operation mode of manual scheling. The planned multimedia monitoring system, including image monitoring, communication and video, information gathering, command and dispatching, can monitor and manage all chain stores, logistics centers and after-sales outlets in real time. After completion, Suning logistics distribution center can realize 24-hour direct door-to-door delivery within 200 km, supporting annual sales of 12 billion yuan.
4.
When white sugar or rock sugar, malt sugar and brown sugar are added with water to make them thick, then the juice or coarse powder of other food or traditional Chinese medicine is added, stirred evenly, and then boiled until they are silky and not sticky. After being cold, they are cut into pieces. Some are cooked in the sugar to add nuts, preserved fruit, etc., mixed, shaping, when cold cut. Candy for chewing, and some can contain pharyngeal food, such as pear paste sugar, mint sugar, sesame sugar, walnut sugar
it can be seen that there are many types of dietotherapy medicated diet, and there are also people who take it in the form of preserves, drinks, fresh juice, etc. because these are familiar to people, we will not repeat them one by one. Each person can choose and determine the usage according to his own condition and dietary needs
5. Candy is a kind of solid or semi-solid sweet food made of white granulated sugar, starch syrup (or other sugar) or permitted sweeteners according to certain proction process requirements.
6. Zhifei biological (300122):
the effect of strengthening sales layout is graally emerging: the medium-term performance is growing steadily, and it is expected that the growth rate of performance will graally accelerate from the medium-term to the end of this year; The focus of this year's performance growth is still the promotion of 23 valent pneumonia, and the stable growth of Hib and acyw135 tetravalent meningitis. The Sichuan vaccine incident in early June showed that the company's 23 price promotion was very strong, and its service ability and emergency handling ability were also very strong
closer cooperation with MSD: the renewal of the contract and the addition of inactivated hepatitis A vaccine means that the cooperation between MSD and MSD is smooth and further strengthened, so as to make preparations for winning more advantageous varieties such as HPV in the future; The follow-up new procts are progressing smoothly, and the procts under research are abundant. In the future, a series of proct echelons will be formed: the GMP certification of self-proced Hib has been inspected on site, waiting for publicity, and AC Hib is expected to obtain the proction number by the end of the year. At present, a batch of proct echelons will be formed for those that have already applied for clinical application and are about to apply, such as acyw135 tetravalent conjugate, dysentery conjugate, EV71 hand foot mouth disease vaccine, 23 valent pneumonia, 15 valent pneumonia conjugate, 13 valent pneumonia conjugate, etc
Zhongyuan Xiehe (600645):
through the acquisition of Heze biological, the instrial chain extends to the downstream. The company's main source of revenue is stem cell detection and storage services, which is in the upstream position of the whole stem cell instry. Through the acquisition of Heze bio, we can not only further enhance the company's R & D strength in the field of stem cell technology, but also extend the company's stem cell business to stem cell research and instrialization, form a relatively complete stem cell instry chain project, complete the company's layout of the stem cell instry, and greatly enhance the company's core competitiveness
supported by the favorable policies of the 12th Five Year Plan. In the 12th Five Year Plan of biological and pharmaceutical instry, it is clearly pointed out that we should actively carry out the research of stem cells and other cell therapy procts, focusing on the research and development of stem cells and immune cells and other cell therapy procts for major diseases such as malignant tumors and autoimmune diseases. In the future, the company will still take stem cell storage as the main source of revenue, but on this basis, the company will rely on Heze biology to further expand the downstream field of stem cells, increase R & D efforts, and the downstream performance of stem cells can be expected to grow
Temple of heaven Biology (600161):
across the two fields of vaccine and blood procts. The company is mainly engaged in the research, proction and management of vaccines, blood procts and other biological procts, which plays an important role in China's health and epidemic prevention system. In 2011, the sales revenue of vaccine and blood procts accounted for 52% and 47% respectively, which was the main source of the company's revenue and profit
vaccine business: entering into a stable period, Xuli Yizhuang base. In 2011, the rise in the volume and price of varicella vaccine was the main factor driving the vaccine business. Affected by the price factor, the vaccine revenue of the headquarters decreased slightly. In view of the fact that the proction capacity of measles series vaccine is close to the upper limit and the price pressure faced by varicella vaccine, we believe that the vaccine business will enter a stable development stage. The scale and centralization of the proction and supply of class I vaccine is an inevitable trend. The construction of the new base in Yizhuang is in line with the development direction of the instry. It is expected that after its completion in 2013, it will open a new growth space for the company and lay a solid foundation for the development of vaccine business
blood procts business: resource advantages guarantee, share the high prosperity of the instry. In 2011, the company's pulp volume was nearly 400 tons, with a year-on-year increase of more than 10%. The rise in volume and price led to a year-on-year increase of 38% in revenue. At the end of last year, the two new pulp stations started to collect pulp, which is expected to exceed the company's expectation of 60 tons of pulp per year; In the short term, the increase of nutrition fee will form a certain cost pressure, but it is expected to form a significant stimulation to the existing pulp station. The endogenous growth of the existing pulp station's pulp proction and the incremental plasma of the new pulp station will enable the company to obtain sufficient development power in the business cycle. At the same time, the company's procts still have some room for price increase. We expect that the company's blood crystal will maintain a growth rate of about 25% in the next two years and become the main force driving the company's growth
the procts in research cannot contribute to the performance in the short term. The proct line under research mainly includes recombinant human interferon D, hand foot mouth disease inactivated vaccine, varicella mumps quadruple vaccine and other procts. The most advanced indication of ifn-9 is multiple sclerosis. The annual sales volume of Schering is 1.2 billion euro. At present, only Schering is allowed to import in China. Interferon D was reported to SFDA for approval at the end of last year and is expected to be approved as soon as this year
Hualan biological (002007):
we believe that the company is the leading enterprise of blood procts enterprises. With the graal maturity of plasma stations in Chongqing and Henan, the company's performance has greater flexibility in the short term; In the long run, the company's strategic layout in the field of biological procts will also win the first opportunity in the development of the market<
Lansheng (600826):
CITIC Guojian's monoclonal antibody drugs have exploded. At present, Lansheng holds 15.18% of CITIC Guojian's shares in total. CITIC Guojian is a leading enterprise of monoclonal antibodies in biomedicine in China. It has the strongest capacity of antibody scale instrialization in China. It has a scientific research team of nearly 100 people led by Guo Yajun, director of the Cancer Institute of the Second Military Medical University. There are as many as 16 monoclonal antibodies in research, most of which are billions of dollars of heavy procts in the international market. In 2010, the income scale of CITIC Guojian was 400 million yuan, a year-on-year increase of 40%, and the net profit was close to 200 million yuan, a year-on-year increase of 118%. In the past two years, the compound growth rates of income and net profit were 75% and 117% respectively. This kind of performance growth was only completed by two procts of "ETAP" and "Xinmeige"
Watson biological (300142):
Da'an pharmaceutical is the only blood proct enterprise in Hebei Province with a single plasma collection station, and has a GMP proction workshop with an annual processing capacity of 200 tons of plasma. From the perspective of plasma station resources, Da'an pharmaceutical currently has three single plasma collection stations (Hejian, Huai'an and Xingyi) in normal operation, and has a capacity of about 100 tons per year. In addition, it is planning to build two single plasma collection stations (Weixian and Luancheng). In terms of proct varieties, Da'an pharmaceutical owns blood albumin, human immunoglobulin (intramuscular injection), human hepatitis B immunoglobulin, human tetanus immunoglobulin and other procts. At present, the main proct human serum albumin is waiting for proction approval. Intravenous injection of human immunoglobulin is in the stage of proction approval number review, and the varieties under research include human coagulation factor VIII, human coagulation factor VIII, human immune globulin, etc Human prothrombin complex, etc
judging from the purchase price, Da'an now reserves 180 tons of plasma, which is worth 108 million yuan based on the net income of 600000 yuan / ton. The company has 100 tons of pulp proction capacity, which may be expanded to about 200 tons in the future, equivalent to an annual profit of 60 million yuan to 120 million yuan, 10 times of PE, with a value of 600 million yuan to 1.2 billion yuan. Therefore, as long as Da'an pharmaceutical can resume proction normally, the current purchase price is relatively reasonable
reinbio (002166):
the company is mainly engaged in the proction and sales of plant extracts, and all shares are held by the management and their relatives before the issue. Qin Benjun, chairman of the board, holds 29.8% of the shares of the company after the issuance and is the actual controller of the company. Plant extract is an emerging instry. Driven by downstream natural medicine, food and other instries, the global market growth rate has maintained at more than 10%. There are many kinds of plant extracts in China, 95% of which are exported. Although the average annual growth rate in recent ten years is more than 20%, the export growth rate in 2005 and 2006 is 26% and 46%, but e to the lack of instry standards, the market concentration is very low. In recent years, the standards of plant extracts in foreign markets have been continuously improved, so the instry growth is graally standardized, It is estimated that the growth rate of plant extract instry in China will maintain above 30% in the next few years. The company ranked tenth in China's plant extract instry, with a revenue of 112 million yuan and a net profit of 22.3 million yuan in 2006. The compound growth rate from 2004 to 2006 was 21% and 20%, and the market share was less than 3%. It has not yet formed a competitive advantage in scale. The revenue of nine main procts accounts for about 75-80% of the company's total revenue. The procts are rich, but the sales scale of single proct is small. The market share of Siraitia grosvenorii and Lycium barbarum extract is 70% and 50%. Due to its advantages in raw materials and market, high foreign demand and great growth potential in the future, it may become the company's top procts in 2-3 years<
rip bio (300119):
recently, the company received two "invention patent awarding notices" issued by the State Intellectual Property Office:
(1) a kind of traditional Chinese medicine granule which can be used to increase the egg proction of poultry, mainly used in the company's preparation proct (Toledo) to improve the proction performance of layers and increase the egg proction rate
(2) an additive composition for prolonging the ration of laying peak can not only prolong the laying peak, but also significantly improve the egg proction
Tiankang bio (002100):
the third quarterly report meets the expectation. From January to September, the company achieved a total operating revenue of 2.1 billion yuan, a year-on-year increase of 20.76%, an operating profit of 102 million yuan, a year-on-year increase of 9.4g%, and a net profit of 86.01 million yuan attributable to the owners of the parent company
the corresponding earnings per share is 0.29 yuan. We believe that the steady growth of FMDV and the substantial increase of investment income (the company holds 44% of the equity of Tiankang animal husbandry, the main business of the company is pig breeding, which contributes 10.93 million yuan in the first three quarters and is expected to reach 30 million yuan in the whole year) are the main reasons for the company's performance growth in the first three quarters
the feed and cotton protein businesses are under great pressure, and they may only break even in the whole year. In our opinion, Shandong Liuhe entered the Henan market, and the capacity expansion of Hongzhan in the past two years mainly depended on reconstruction, which made the proct market competitive advantage of Henan Hongzhan weaken year by year. We expect that the net profit margin of the subsidiary may be less than 1% (the net profit margin of the company headquarters is only about 1.5%). For cotton protein business, we estimated that the crushing scale of last year was about 150000 tons of cottonseed, and the purchase volume in 2011 was expected to be the same as that of last year; As the gross profit margin of cotton oil sales is still negative at present, and the capacity profit margin is insufficient (the design capacity of Aksu and Kuitun proction lines is 240000 tons, and the full proction capacity can reach 300000 tons), the whole plate may continue to maintain profit and loss balance in 2011 (according to the data of the parent company and the consolidated financial statements, Aksu and Kuitun may lose more than 10 million yuan in the first three quarters)
the growth of vaccine sector slowed down, and foot-and-mouth disease vaccine contributed about 80% of the revenue. We estimate that 80% of the company's vaccine revenue comes from the contribution of foot-and-mouth disease vaccine (there are five proction units in China, so the market competition is not too fierce compared with other varieties). At present, the market share has reached about 25%. We expect that the year-on-year growth of the company's vaccine sales revenue in 2011 is expected to reach about 10%, of which the growth of foot-and-mouth disease is slightly higher, and the annual revenue of other vaccines is likely to decline e to the market price decline and other reasons
China animal husbandry Co., Ltd. (600195):
the company is a leading enterprise in China's animal husbandry instry, and its main income and profit come from the designated proction of national compulsory immunization animal vaccine. The company proces four kinds of national compulsory immunization vaccines: avian influenza vaccine, foot-and-mouth disease vaccine, pig blue ear vaccine and classical swine fever vaccine. The market share of these procts is high. The main driving factors for the growth of the company's biological procts are as follows: the increase of national compulsory immunization vaccine varieties, the stock of livestock and poultry and the large-scale breeding rate. As it is difficult to predict the adjustment of national compulsory immunization varieties, we will not consider it for the time being. Considering that the company's procts have certain advantages, and the stock and large-scale breeding rate of livestock and poultry will continue to rise in the long run, we believe that the company's biological procts business will maintain a stable growth
Animals
the effect of strengthening sales layout is graally emerging: the medium-term performance is growing steadily, and it is expected that the growth rate of performance will graally accelerate from the medium-term to the end of this year; The focus of this year's performance growth is still the promotion of 23 valent pneumonia, and the stable growth of Hib and acyw135 tetravalent meningitis. The Sichuan vaccine incident in early June showed that the company's 23 price promotion was very strong, and its service ability and emergency handling ability were also very strong
closer cooperation with MSD: the renewal of the contract and the addition of inactivated hepatitis A vaccine means that the cooperation between MSD and MSD is smooth and further strengthened, so as to make preparations for winning more advantageous varieties such as HPV in the future; The follow-up new procts are progressing smoothly, and the procts under research are abundant. In the future, a series of proct echelons will be formed: the GMP certification of self-proced Hib has been inspected on site, waiting for publicity, and AC Hib is expected to obtain the proction number by the end of the year. At present, a batch of proct echelons will be formed for those that have already applied for clinical application and are about to apply, such as acyw135 tetravalent conjugate, dysentery conjugate, EV71 hand foot mouth disease vaccine, 23 valent pneumonia, 15 valent pneumonia conjugate, 13 valent pneumonia conjugate, etc
Zhongyuan Xiehe (600645):
through the acquisition of Heze biological, the instrial chain extends to the downstream. The company's main source of revenue is stem cell detection and storage services, which is in the upstream position of the whole stem cell instry. Through the acquisition of Heze bio, we can not only further enhance the company's R & D strength in the field of stem cell technology, but also extend the company's stem cell business to stem cell research and instrialization, form a relatively complete stem cell instry chain project, complete the company's layout of the stem cell instry, and greatly enhance the company's core competitiveness
supported by the favorable policies of the 12th Five Year Plan. In the 12th Five Year Plan of biological and pharmaceutical instry, it is clearly pointed out that we should actively carry out the research of stem cells and other cell therapy procts, focusing on the research and development of stem cells and immune cells and other cell therapy procts for major diseases such as malignant tumors and autoimmune diseases. In the future, the company will still take stem cell storage as the main source of revenue, but on this basis, the company will rely on Heze biology to further expand the downstream field of stem cells, increase R & D efforts, and the downstream performance of stem cells can be expected to grow
Temple of heaven Biology (600161):
across the two fields of vaccine and blood procts. The company is mainly engaged in the research, proction and management of vaccines, blood procts and other biological procts, which plays an important role in China's health and epidemic prevention system. In 2011, the sales revenue of vaccine and blood procts accounted for 52% and 47% respectively, which was the main source of the company's revenue and profit
vaccine business: entering into a stable period, Xuli Yizhuang base. In 2011, the rise in the volume and price of varicella vaccine was the main factor driving the vaccine business. Affected by the price factor, the vaccine revenue of the headquarters decreased slightly. In view of the fact that the proction capacity of measles series vaccine is close to the upper limit and the price pressure faced by varicella vaccine, we believe that the vaccine business will enter a stable development stage. The scale and centralization of the proction and supply of class I vaccine is an inevitable trend. The construction of the new base in Yizhuang is in line with the development direction of the instry. It is expected that after its completion in 2013, it will open a new growth space for the company and lay a solid foundation for the development of vaccine business
blood procts business: resource advantages guarantee, share the high prosperity of the instry. In 2011, the company's pulp volume was nearly 400 tons, with a year-on-year increase of more than 10%. The rise in volume and price led to a year-on-year increase of 38% in revenue. At the end of last year, the two new pulp stations started to collect pulp, which is expected to exceed the company's expectation of 60 tons of pulp per year; In the short term, the increase of nutrition fee will form a certain cost pressure, but it is expected to form a significant stimulation to the existing pulp station. The endogenous growth of the existing pulp station's pulp proction and the incremental plasma of the new pulp station will enable the company to obtain sufficient development power in the business cycle. At the same time, the company's procts still have some room for price increase. We expect that the company's blood crystal will maintain a growth rate of about 25% in the next two years and become the main force driving the company's growth
the procts in research cannot contribute to the performance in the short term. The proct line under research mainly includes recombinant human interferon D, hand foot mouth disease inactivated vaccine, varicella mumps quadruple vaccine and other procts. The most advanced indication of ifn-9 is multiple sclerosis. The annual sales volume of Schering is 1.2 billion euro. At present, only Schering is allowed to import in China. Interferon D was reported to SFDA for approval at the end of last year and is expected to be approved as soon as this year
Hualan biological (002007):
we believe that the company is the leading enterprise of blood procts enterprises. With the graal maturity of plasma stations in Chongqing and Henan, the company's performance has greater flexibility in the short term; In the long run, the company's strategic layout in the field of biological procts will also win the first opportunity in the development of the market<
Lansheng (600826):
CITIC Guojian's monoclonal antibody drugs have exploded. At present, Lansheng holds 15.18% of CITIC Guojian's shares in total. CITIC Guojian is a leading enterprise of monoclonal antibodies in biomedicine in China. It has the strongest capacity of antibody scale instrialization in China. It has a scientific research team of nearly 100 people led by Guo Yajun, director of the Cancer Institute of the Second Military Medical University. There are as many as 16 monoclonal antibodies in research, most of which are billions of dollars of heavy procts in the international market. In 2010, the income scale of CITIC Guojian was 400 million yuan, a year-on-year increase of 40%, and the net profit was close to 200 million yuan, a year-on-year increase of 118%. In the past two years, the compound growth rates of income and net profit were 75% and 117% respectively. This kind of performance growth was only completed by two procts of "ETAP" and "Xinmeige"
Watson biological (300142):
Da'an pharmaceutical is the only blood proct enterprise in Hebei Province with a single plasma collection station, and has a GMP proction workshop with an annual processing capacity of 200 tons of plasma. From the perspective of plasma station resources, Da'an pharmaceutical currently has three single plasma collection stations (Hejian, Huai'an and Xingyi) in normal operation, and has a capacity of about 100 tons per year. In addition, it is planning to build two single plasma collection stations (Weixian and Luancheng). In terms of proct varieties, Da'an pharmaceutical owns blood albumin, human immunoglobulin (intramuscular injection), human hepatitis B immunoglobulin, human tetanus immunoglobulin and other procts. At present, the main proct human serum albumin is waiting for proction approval. Intravenous injection of human immunoglobulin is in the stage of proction approval number review, and the varieties under research include human coagulation factor VIII, human coagulation factor VIII, human immune globulin, etc Human prothrombin complex, etc
judging from the purchase price, Da'an now reserves 180 tons of plasma, which is worth 108 million yuan based on the net income of 600000 yuan / ton. The company has 100 tons of pulp proction capacity, which may be expanded to about 200 tons in the future, equivalent to an annual profit of 60 million yuan to 120 million yuan, 10 times of PE, with a value of 600 million yuan to 1.2 billion yuan. Therefore, as long as Da'an pharmaceutical can resume proction normally, the current purchase price is relatively reasonable
reinbio (002166):
the company is mainly engaged in the proction and sales of plant extracts, and all shares are held by the management and their relatives before the issue. Qin Benjun, chairman of the board, holds 29.8% of the shares of the company after the issuance and is the actual controller of the company. Plant extract is an emerging instry. Driven by downstream natural medicine, food and other instries, the global market growth rate has maintained at more than 10%. There are many kinds of plant extracts in China, 95% of which are exported. Although the average annual growth rate in recent ten years is more than 20%, the export growth rate in 2005 and 2006 is 26% and 46%, but e to the lack of instry standards, the market concentration is very low. In recent years, the standards of plant extracts in foreign markets have been continuously improved, so the instry growth is graally standardized, It is estimated that the growth rate of plant extract instry in China will maintain above 30% in the next few years. The company ranked tenth in China's plant extract instry, with a revenue of 112 million yuan and a net profit of 22.3 million yuan in 2006. The compound growth rate from 2004 to 2006 was 21% and 20%, and the market share was less than 3%. It has not yet formed a competitive advantage in scale. The revenue of nine main procts accounts for about 75-80% of the company's total revenue. The procts are rich, but the sales scale of single proct is small. The market share of Siraitia grosvenorii and Lycium barbarum extract is 70% and 50%. Due to its advantages in raw materials and market, high foreign demand and great growth potential in the future, it may become the company's top procts in 2-3 years<
rip bio (300119):
recently, the company received two "invention patent awarding notices" issued by the State Intellectual Property Office:
(1) a kind of traditional Chinese medicine granule which can be used to increase the egg proction of poultry, mainly used in the company's preparation proct (Toledo) to improve the proction performance of layers and increase the egg proction rate
(2) an additive composition for prolonging the ration of laying peak can not only prolong the laying peak, but also significantly improve the egg proction
Tiankang bio (002100):
the third quarterly report meets the expectation. From January to September, the company achieved a total operating revenue of 2.1 billion yuan, a year-on-year increase of 20.76%, an operating profit of 102 million yuan, a year-on-year increase of 9.4g%, and a net profit of 86.01 million yuan attributable to the owners of the parent company
the corresponding earnings per share is 0.29 yuan. We believe that the steady growth of FMDV and the substantial increase of investment income (the company holds 44% of the equity of Tiankang animal husbandry, the main business of the company is pig breeding, which contributes 10.93 million yuan in the first three quarters and is expected to reach 30 million yuan in the whole year) are the main reasons for the company's performance growth in the first three quarters
the feed and cotton protein businesses are under great pressure, and they may only break even in the whole year. In our opinion, Shandong Liuhe entered the Henan market, and the capacity expansion of Hongzhan in the past two years mainly depended on reconstruction, which made the proct market competitive advantage of Henan Hongzhan weaken year by year. We expect that the net profit margin of the subsidiary may be less than 1% (the net profit margin of the company headquarters is only about 1.5%). For cotton protein business, we estimated that the crushing scale of last year was about 150000 tons of cottonseed, and the purchase volume in 2011 was expected to be the same as that of last year; As the gross profit margin of cotton oil sales is still negative at present, and the capacity profit margin is insufficient (the design capacity of Aksu and Kuitun proction lines is 240000 tons, and the full proction capacity can reach 300000 tons), the whole plate may continue to maintain profit and loss balance in 2011 (according to the data of the parent company and the consolidated financial statements, Aksu and Kuitun may lose more than 10 million yuan in the first three quarters)
the growth of vaccine sector slowed down, and foot-and-mouth disease vaccine contributed about 80% of the revenue. We estimate that 80% of the company's vaccine revenue comes from the contribution of foot-and-mouth disease vaccine (there are five proction units in China, so the market competition is not too fierce compared with other varieties). At present, the market share has reached about 25%. We expect that the year-on-year growth of the company's vaccine sales revenue in 2011 is expected to reach about 10%, of which the growth of foot-and-mouth disease is slightly higher, and the annual revenue of other vaccines is likely to decline e to the market price decline and other reasons
China animal husbandry Co., Ltd. (600195):
the company is a leading enterprise in China's animal husbandry instry, and its main income and profit come from the designated proction of national compulsory immunization animal vaccine. The company proces four kinds of national compulsory immunization vaccines: avian influenza vaccine, foot-and-mouth disease vaccine, pig blue ear vaccine and classical swine fever vaccine. The market share of these procts is high. The main driving factors for the growth of the company's biological procts are as follows: the increase of national compulsory immunization vaccine varieties, the stock of livestock and poultry and the large-scale breeding rate. As it is difficult to predict the adjustment of national compulsory immunization varieties, we will not consider it for the time being. Considering that the company's procts have certain advantages, and the stock and large-scale breeding rate of livestock and poultry will continue to rise in the long run, we believe that the company's biological procts business will maintain a stable growth
Animals
7. Changchun hi tech: Changchun hi tech instry (Group) Co., Ltd. was established in June 1993. Its shares were listed on the main board of Shenzhen Stock Exchange on December 18, 1996, becoming one of the earliest listed companies in Northeast China. The company's main business is biopharmaceutical, Chinese patent medicine proction and sales, supplemented by real estate development, property management, etc< Chongqing Zhifei Biological Procts Co., Ltd. was established in 1995 and listed on the Shenzhen Stock Exchange on September 28, 2010. With a registered capital of 400 million yuan, the company has three wholly-owned subsidiaries, including high-tech enterprises Beijing Lvzhu biopharmaceutical Co., Ltd., Anhui longkema biopharmaceutical Co., Ltd. and Chongqing Zhiren Biotechnology Co., Ltd. It is a biological high-tech enterprise integrating vaccine R & D, proction and sales
Kangtai biological: Shenzhen Kangtai Biological Procts Co., Ltd., established in August 1988, is one of the high-tech enterprises in Shenzhen, mainly engaged in the R & D, proction and sales of biological procts. In 2008, Kangtai biological carried out strategic capital restructuring. In October 1987, the State Planning Commission approved that the Ministry of health should organize the introction of instrial proction technology of genetically engineered recombinant (yeast) hepatitis B vaccine for construction in Beijing and Shenzhen
Watson Biotechnology: Yunnan Watson Biotechnology Co., Ltd. is a biopharmaceutical enterprise specializing in the R & D, proction and sales of human vaccine procts, and is committed to providing safe, effective, high-quality and advanced human vaccine procts to domestic and foreign markets. On November 12, 2010, Yunnan Watson Biotechnology Co., Ltd. was successfully listed on Shenzhen Stock Exchange, becoming the first enterprise in Yunnan Province to be listed on China growth enterprise market
Hualan Bioengineering: Hualan Bioengineering Co., Ltd., formerly known as Hualan Bioengineering Co., Ltd., was established in 1992. It is a national key high-tech enterprise engaged in research and development and proction of blood procts, and was the first to pass GMP certification in the blood procts instry in 1998. As a national designated large-scale biological procts proction enterprise, the company has undertaken a number of national, provincial and municipal scientific and technological projects.
Kangtai biological: Shenzhen Kangtai Biological Procts Co., Ltd., established in August 1988, is one of the high-tech enterprises in Shenzhen, mainly engaged in the R & D, proction and sales of biological procts. In 2008, Kangtai biological carried out strategic capital restructuring. In October 1987, the State Planning Commission approved that the Ministry of health should organize the introction of instrial proction technology of genetically engineered recombinant (yeast) hepatitis B vaccine for construction in Beijing and Shenzhen
Watson Biotechnology: Yunnan Watson Biotechnology Co., Ltd. is a biopharmaceutical enterprise specializing in the R & D, proction and sales of human vaccine procts, and is committed to providing safe, effective, high-quality and advanced human vaccine procts to domestic and foreign markets. On November 12, 2010, Yunnan Watson Biotechnology Co., Ltd. was successfully listed on Shenzhen Stock Exchange, becoming the first enterprise in Yunnan Province to be listed on China growth enterprise market
Hualan Bioengineering: Hualan Bioengineering Co., Ltd., formerly known as Hualan Bioengineering Co., Ltd., was established in 1992. It is a national key high-tech enterprise engaged in research and development and proction of blood procts, and was the first to pass GMP certification in the blood procts instry in 1998. As a national designated large-scale biological procts proction enterprise, the company has undertaken a number of national, provincial and municipal scientific and technological projects.
8. Bio vaccine concept stock
China animal husbandry (600195) Co., Ltd. is the first bird flu vaccine manufacturer approved by the Ministry of agriculture
Rhine bio (002166) company's business includes extracting and manufacturing & quot; Tamiflu & quot; Shikimic acid, the raw material of the proct
the influenza vaccine developed by Haiwang intelon, a subsidiary of Haiwang biological (000078) company, is the second generation influenza vaccine in the world and the first in China
Daan gene (002030) Co., Ltd. and its joint venture Guangzhou huashengda Co., Ltd. have jointly developed a new human influenza A (H1N1) virus nucleic acid detection kit and a universal influenza A virus nucleic acid detection kit, and have obtained the registration certificate of medical devices for influenza A (H1N1) virus detection kit. In the national key new proct plan issued by the Ministry of science and technology, the company's influenza A (H1N1) virus nucleic acid detection kit (PCR fluorescent probe method) (No. 2010gre01001) was confirmed as a national key new proct
the proct group of Northeast Pharmaceutical (000597) company covers more than 200 kinds of seven categories, including vitamins, anti infection, family planning and hormone, antiviral, brain circulation and intelligence promoting drugs, digestive system, anesthesia and psychiatry< Beijing Sihuan biopharmaceutical Co., Ltd., a subsidiary of Sihuan bio (000518), is the first high-tech enterprise in China to engage in the research, pilot test, proction and sales of genetic engineering drugs and diagnostic reagents, integrating science, instry and trade.
Lukang Pharmaceutical (600789) Co., Ltd., one of the antibiotic proction bases in China, is an enterprise with a relatively complete proction chain of three major parent nuclei of semi synthetic antibodies, The company has also realized the transformation from traditional antibiotic proction to haploidentical antibody proction<
Inner Mongolia biopharmaceutical factory of Jinyu group (600201) is the only enterprise procing livestock and poultry vaccine procts in the autonomous region
Shenghua Baike (600226) is a recessive leading enterprise in domestic pesticide, veterinary medicine, animal vaccine and zirconium instries. Its main veterinary procts cover three major fields: animal vaccine, animal antibiotic preparation and animal nutrition medicine, with complete instrial chain, The competition ability is outstanding
Lianhuan Pharmaceutical (600513) company has inactivated avian influenza vaccine (H9 subtype, f strain), which has been approved by the Ministry of agriculture for veterinary drug proction and put into proction
Hualan biological (002007) Co., Ltd. and Chinese Academy of Military Medical Sciences jointly undertake the pre clinical research of human avian influenza vaccine. After the verification and evaluation, the company's pandemic influenza split vaccine will enter the clinical stage
Beijing Institute of biological procts and Chinese Academy of Military Medical Sciences, the controlling shareholders of Tiantan Biological (600161) Co., Ltd., will jointly undertake the research and development of the second human avian influenza vaccine project in mainland China
China animal husbandry (600195) Co., Ltd. is the first bird flu vaccine manufacturer approved by the Ministry of agriculture
Rhine bio (002166) company's business includes extracting and manufacturing & quot; Tamiflu & quot; Shikimic acid, the raw material of the proct
the influenza vaccine developed by Haiwang intelon, a subsidiary of Haiwang biological (000078) company, is the second generation influenza vaccine in the world and the first in China
Daan gene (002030) Co., Ltd. and its joint venture Guangzhou huashengda Co., Ltd. have jointly developed a new human influenza A (H1N1) virus nucleic acid detection kit and a universal influenza A virus nucleic acid detection kit, and have obtained the registration certificate of medical devices for influenza A (H1N1) virus detection kit. In the national key new proct plan issued by the Ministry of science and technology, the company's influenza A (H1N1) virus nucleic acid detection kit (PCR fluorescent probe method) (No. 2010gre01001) was confirmed as a national key new proct
the proct group of Northeast Pharmaceutical (000597) company covers more than 200 kinds of seven categories, including vitamins, anti infection, family planning and hormone, antiviral, brain circulation and intelligence promoting drugs, digestive system, anesthesia and psychiatry< Beijing Sihuan biopharmaceutical Co., Ltd., a subsidiary of Sihuan bio (000518), is the first high-tech enterprise in China to engage in the research, pilot test, proction and sales of genetic engineering drugs and diagnostic reagents, integrating science, instry and trade.
Lukang Pharmaceutical (600789) Co., Ltd., one of the antibiotic proction bases in China, is an enterprise with a relatively complete proction chain of three major parent nuclei of semi synthetic antibodies, The company has also realized the transformation from traditional antibiotic proction to haploidentical antibody proction<
Inner Mongolia biopharmaceutical factory of Jinyu group (600201) is the only enterprise procing livestock and poultry vaccine procts in the autonomous region
Shenghua Baike (600226) is a recessive leading enterprise in domestic pesticide, veterinary medicine, animal vaccine and zirconium instries. Its main veterinary procts cover three major fields: animal vaccine, animal antibiotic preparation and animal nutrition medicine, with complete instrial chain, The competition ability is outstanding
Lianhuan Pharmaceutical (600513) company has inactivated avian influenza vaccine (H9 subtype, f strain), which has been approved by the Ministry of agriculture for veterinary drug proction and put into proction
Hualan biological (002007) Co., Ltd. and Chinese Academy of Military Medical Sciences jointly undertake the pre clinical research of human avian influenza vaccine. After the verification and evaluation, the company's pandemic influenza split vaccine will enter the clinical stage
Beijing Institute of biological procts and Chinese Academy of Military Medical Sciences, the controlling shareholders of Tiantan Biological (600161) Co., Ltd., will jointly undertake the research and development of the second human avian influenza vaccine project in mainland China
Hot content